Chimeras of
Chimeric polypeptides useful as immunogens for inducing protective immune responses and neutralizing antibodies against Shiga toxin (Stx) in mammals. More specifically, chimeric polypeptides having a monomer of the homopentameric B subunit of the Shiga 2 toxin fused to the N-terminus of a monomer of Brucella lumazine synthase, and to oligomeric protein complexes formed from said chimeric polypeptides. Polynucleotides and vectors encoding said chimeric polypeptides, transgenic cells having said polynucleotides and vectors, pharmaceutical compositions, such as a vaccine, having said chimeric polypeptides and chimeric polynucleotides, antibodies which bind to the chimeric polypeptides, a method for obtaining antibodies which bind specifically to the subunit B of the Shiga 2 toxin and methods of lowering the bacterial load of enterohemorrhagic Escherichia coli in mammals, which can be used for prevention of inter alia, hemolytic-ureic syndrome (HUS), are also provided.
1. A chimeric protein, comprising from amino-terminus to carboxy-terminus a Shiga toxin 2 subunit B (Stx2B) monomer, a peptide linker, and a Brucella lumazine synthase (BLS) monomer, wherein:
the Stx2B monomer comprises a peptide having at least 95% identity to the amino acid sequence of SEQ ID NO:1,
the BLS monomer comprises a peptide having at least 95% identity to amino acids 9-158 of SEQ ID NO:9, and
the chimeric protein is capable of: (a) binding to globotriaosylceramide (Gb3) and (b) eliciting cross-reactive antibodies against Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) and/or against allelic variants of Stx2.
2. The chimeric protein of claim 1 , wherein the peptide linker ranges from 2 amino acids to 20 amino acids in length.
3. The chimeric protein of claim 2 , wherein the peptide linker comprises a Gly-Ser flexible linker.
4. The chimeric protein of claim 3 , wherein the Gly-Ser flexible linker is comprised of amino acids 73-77 of SEQ ID NO:3, amino acids 73-82 of SEQ ID NO:5, or amino acids 73-87 of SEQ ID NO:7.
5. The chimeric protein of claim 1 , wherein the Stx2B monomer comprises or consists of the amino acid sequence of SEQ ID NO:1.
6. The chimeric protein of claim 1 , wherein the BLS monomer comprises or consists of amino acids 9-158 of SEQ ID NO:9.
7. The chimeric protein of claim 1 , wherein the chimeric protein has at least 95% identity to the amino acid sequence of any one of SEQ ID NOS:3, 5, and 7.
8. The chimeric protein of claim 1 , wherein the chimeric protein comprises or consists of the amino acid sequence of any one of SEQ ID NOS:3, 5, and 7.
9. A protein oligomeric complex, comprising a dimer of pentamers of the chimeric protein of claim 1 .
10. A pharmaceutical composition, comprising the protein oligomeric complex of claim 9 and a pharmaceutically acceptable carrier.
11. The pharmaceutical composition of claim 10 , further comprising an adjuvant.
12. The pharmaceutical composition of claim 11 , wherein the adjuvant is selected from the group consisting of Freund's adjuvant (FA), an aluminum compound, a liposome, a non-ionic block polymer, a saponin, and dimethyl dioctadecylamonium bromide (DDA).
13. The pharmaceutical composition of claim 11 , wherein the adjuvant is an aluminum hydroxide gel.
14. The pharmaceutical composition of claim 11 , wherein the adjuvant is Freund's adjuvant.
15. A method for producing a neutralizing antibody against Shiga toxin 2 subunit B (Stx2B), the method comprising the steps of:
(a) administering to a mammal an effective amount of the pharmaceutical composition of claim 10 for a time sufficient to elicit neutralizing antibodies against Stx2B, and
(b) obtaining from the mammal neutralizing antibodies and/or cells capable of producing the neutralizing antibodies.
16. The method claim 15 , wherein the pharmaceutical composition further comprises an adjuvant.
17. The method of claim 15 , wherein the protein oligomeric complex of the pharmaceutical composition is comprised of a chimeric protein having at least 95% identity to the amino acid sequence of any one of SEQ ID NOS:3, 5, and 7.
18. The method of claim 15 , wherein the protein oligomeric complex of the pharmaceutical composition is comprised of a chimeric protein comprises or consists of the amino acid sequence of any one of SEQ ID NOS:3, 5, and 7.
19. The method of claim 15 , wherein the pharmaceutical composition elicits cross-neutralizing antibodies against Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2).
20. The method of claim 15 , wherein the pharmaceutical composition elicits cross-neutralizing antibodies against Shiga toxin 2 (Stx2) and allelic variants thereof.
21. The method of claim 20 , wherein the antibodies cross-neutralize Stx2 allelic variant Stx2c, Stx2d, or both.
22. A method of inducing a protective immune response against hemolytic-uremic syndrome (HUS), comprising administering to a mammalian subject an effective amount of the pharmaceutical composition of claim 10 for a time sufficient to elicit a protective immune response.
23. The method claim 22 , wherein the pharmaceutical composition further comprises an adjuvant.
24. The method of claim 22 , wherein the protein oligomeric complex of the pharmaceutical composition is comprised of a chimeric protein having at least 95% identity to the amino acid sequence of any one of SEQ ID NOS:3, 5, and 7.
25. The method of claim 22 , wherein the protein oligomeric complex of the pharmaceutical composition is comprised of a chimeric protein comprises or consists of the amino acid sequence of any one of SEQ ID NOS:3, 5, and 7.